Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055363024> ?p ?o ?g. }
- W2055363024 endingPage "1027" @default.
- W2055363024 startingPage "1022" @default.
- W2055363024 abstract "Background. In this prospective, randomized, open-label, single-center study, we compared the efficacy and safety of two anti-interleukin-2 receptor monoclonal antibodies combined with triple immunosuppression. Methods. The adult recipients of at least one human leukocyte antigen-mismatched deceased donor renal graft on cyclosporine microemulsion, mycophenolate mofetil, and methylprednisolone were randomized to induction with basiliximab or daclizumab, given in standard doses. An intent-to-treat analysis of 1-year data assessed the incidence of acute rejections, graft function, patient and graft survival, and safety of this therapy. Results. Two hundred twelve patients were studied. At 12 months, 11 (10.3%) and 10 (9.5%) patients experienced biopsy-confirmed first acute rejection in basiliximab and daclizumab groups, respectively. Estimated glomerular filtration rate was 69±19 mL/min/1.73 m2 in the basiliximab and 66±21 mL/min/1.73 m2 in the daclizumab group. Patient survival was 97.2% with basiliximab and 97.1% with daclizumab, and graft survival was 94.4% vs. 90.5%, respectively. Hospital treatment was required for 50 and 59 infections in basiliximab and daclizumab groups, respectively. One renal cell carcinoma of native kidney and one basal cell carcinoma were detected in the basiliximab group, and one melanoma of skin in the daclizumab group. One hypersensitivity reaction was observed with daclizumab. No significant differences were found between the groups. Conclusion. Basiliximab or daclizumab combined with triple therapy was an efficient and a safe immunosuppression strategy, demonstrated with low incidence of acute rejections, excellent graft function, high survival rates, and acceptable adverse event profile in adult recipients within the 1st year after deceased donor renal transplantation." @default.
- W2055363024 created "2016-06-24" @default.
- W2055363024 creator A5022581162 @default.
- W2055363024 creator A5060593826 @default.
- W2055363024 creator A5064560318 @default.
- W2055363024 creator A5065105869 @default.
- W2055363024 creator A5070690795 @default.
- W2055363024 creator A5075696310 @default.
- W2055363024 creator A5082718926 @default.
- W2055363024 date "2010-04-27" @default.
- W2055363024 modified "2023-09-23" @default.
- W2055363024 title "Basiliximab Versus Daclizumab Combined With Triple Immunosuppression in Deceased Donor Renal Transplantation: A Prospective, Randomized Study" @default.
- W2055363024 cites W1756759934 @default.
- W2055363024 cites W1980998626 @default.
- W2055363024 cites W1985137297 @default.
- W2055363024 cites W1987732789 @default.
- W2055363024 cites W1990612749 @default.
- W2055363024 cites W1995791071 @default.
- W2055363024 cites W2009236577 @default.
- W2055363024 cites W2019306593 @default.
- W2055363024 cites W2025287011 @default.
- W2055363024 cites W2034818671 @default.
- W2055363024 cites W2043957629 @default.
- W2055363024 cites W2047455089 @default.
- W2055363024 cites W2051891058 @default.
- W2055363024 cites W2070224385 @default.
- W2055363024 cites W2072030208 @default.
- W2055363024 cites W2076451571 @default.
- W2055363024 cites W2078633650 @default.
- W2055363024 cites W2089268585 @default.
- W2055363024 cites W2098773501 @default.
- W2055363024 cites W2110079652 @default.
- W2055363024 cites W2112333205 @default.
- W2055363024 cites W2123720448 @default.
- W2055363024 cites W2135110539 @default.
- W2055363024 cites W2333378480 @default.
- W2055363024 cites W4252727071 @default.
- W2055363024 cites W68282923 @default.
- W2055363024 doi "https://doi.org/10.1097/tp.0b013e3181d02496" @default.
- W2055363024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20075788" @default.
- W2055363024 hasPublicationYear "2010" @default.
- W2055363024 type Work @default.
- W2055363024 sameAs 2055363024 @default.
- W2055363024 citedByCount "38" @default.
- W2055363024 countsByYear W20553630242012 @default.
- W2055363024 countsByYear W20553630242013 @default.
- W2055363024 countsByYear W20553630242014 @default.
- W2055363024 countsByYear W20553630242015 @default.
- W2055363024 countsByYear W20553630242016 @default.
- W2055363024 countsByYear W20553630242017 @default.
- W2055363024 countsByYear W20553630242019 @default.
- W2055363024 countsByYear W20553630242020 @default.
- W2055363024 countsByYear W20553630242021 @default.
- W2055363024 crossrefType "journal-article" @default.
- W2055363024 hasAuthorship W2055363024A5022581162 @default.
- W2055363024 hasAuthorship W2055363024A5060593826 @default.
- W2055363024 hasAuthorship W2055363024A5064560318 @default.
- W2055363024 hasAuthorship W2055363024A5065105869 @default.
- W2055363024 hasAuthorship W2055363024A5070690795 @default.
- W2055363024 hasAuthorship W2055363024A5075696310 @default.
- W2055363024 hasAuthorship W2055363024A5082718926 @default.
- W2055363024 hasBestOaLocation W20553630241 @default.
- W2055363024 hasConcept C126322002 @default.
- W2055363024 hasConcept C126894567 @default.
- W2055363024 hasConcept C141071460 @default.
- W2055363024 hasConcept C2779719350 @default.
- W2055363024 hasConcept C2780252810 @default.
- W2055363024 hasConcept C2780303639 @default.
- W2055363024 hasConcept C2781307858 @default.
- W2055363024 hasConcept C2909675724 @default.
- W2055363024 hasConcept C2911091166 @default.
- W2055363024 hasConcept C71924100 @default.
- W2055363024 hasConcept C90924648 @default.
- W2055363024 hasConceptScore W2055363024C126322002 @default.
- W2055363024 hasConceptScore W2055363024C126894567 @default.
- W2055363024 hasConceptScore W2055363024C141071460 @default.
- W2055363024 hasConceptScore W2055363024C2779719350 @default.
- W2055363024 hasConceptScore W2055363024C2780252810 @default.
- W2055363024 hasConceptScore W2055363024C2780303639 @default.
- W2055363024 hasConceptScore W2055363024C2781307858 @default.
- W2055363024 hasConceptScore W2055363024C2909675724 @default.
- W2055363024 hasConceptScore W2055363024C2911091166 @default.
- W2055363024 hasConceptScore W2055363024C71924100 @default.
- W2055363024 hasConceptScore W2055363024C90924648 @default.
- W2055363024 hasIssue "8" @default.
- W2055363024 hasLocation W20553630241 @default.
- W2055363024 hasLocation W20553630242 @default.
- W2055363024 hasLocation W20553630243 @default.
- W2055363024 hasOpenAccess W2055363024 @default.
- W2055363024 hasPrimaryLocation W20553630241 @default.
- W2055363024 hasRelatedWork W1989013906 @default.
- W2055363024 hasRelatedWork W1990658516 @default.
- W2055363024 hasRelatedWork W2038585270 @default.
- W2055363024 hasRelatedWork W2065729608 @default.
- W2055363024 hasRelatedWork W2099888322 @default.
- W2055363024 hasRelatedWork W2137221584 @default.
- W2055363024 hasRelatedWork W2540384661 @default.
- W2055363024 hasRelatedWork W2917955192 @default.